Evelo Biosciences (EVLO)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Sep 18, 2024 02:44 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Evelo Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 108 | 115 | 92 | 86 |
Income After Depreciation & Amortization | 0 | -108 | -115 | -92 | -86 |
Non-Operating Income | NA | 0 | -3 | -1 | 1 |
Interest Expense | NA | 5 | 4 | 0 | 0 |
Pretax Income | NA | -114 | -122 | -93 | -85 |
Income Taxes | NA | 1 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -115 | -122 | -94 | -85 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -115 | -122 | -94 | -85 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -106 | -113 | -90 | -85 |
Depreciation & Amortization (Cash Flow) | NA | 2 | 2 | 2 | 2 |
Income After Depreciation & Amortization | 0 | -108 | -115 | -92 | -86 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 4.36 | 2.65 | 1.97 | 1.60 |
Diluted EPS Before Non-Recurring Items | NA | -26.20 | -45.00 | -47.40 | -53.40 |
Diluted Net EPS (GAAP) | NA | -26.20 | -46.20 | -47.40 | -53.40 |
Fiscal Year end for Evelo Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | 0.00 | 0.00 |
Cost Of Goods | NA | NA | NA | 0.00 | NA |
Gross Profit | NA | NA | NA | 0.00 | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 11.18 | 19.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | -11.18 | -19.57 |
Non-Operating Income | NA | NA | NA | -0.04 | 0.07 |
Interest Expense | NA | NA | NA | 1.16 | 1.37 |
Pretax Income | NA | NA | NA | -12.38 | -20.87 |
Income Taxes | NA | NA | NA | -0.02 | 0.23 |
Minority Interest | NA | NA | NA | 0.00 | NA |
Investment Gains/Losses | NA | NA | NA | 0.00 | NA |
Other Income/Charges | NA | NA | NA | 0.00 | NA |
Income From Cont. Operations | NA | NA | NA | -12.36 | -21.10 |
Extras & Discontinued Operations | NA | NA | NA | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | NA | -12.36 | -21.10 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | 17.38 | 5.58 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | -0.66 | -3.55 |
Diluted Net EPS (GAAP) | NA | NA | NA | -0.71 | -3.78 |